Abstract:Background Evaluating the contribution of glucocorticoid use to organ damage in systemic lupus erythematosus is confounded by glucocorticoid use in active disease. We sought to determine the independence of the contribution of glucocorticoid use to damage accrual from associations with disease activity by analysing patients without measurable disease activity. Methods Patients (age >18 years) who met the criteria for systemic lupus erythematosus were recruited from 13 centres in Australia, Indonesia, Japan, Malaysia, the Philippines, Singapore, Taiwan, and Thailand, and followed longitudinally. Disease activity (Systemic Lupus Erythetnatosus Disease Activity Index 2000 [SLEDAI-2K] and Physician Global Assessment [PGA] scores) and treatment details were recorded at each visit (at least once every 6 months), and organ damage measured annually according to the Systemic Lupus International Collaborating Clinics Damage Index (SDI). Glucocorticoid use during the study period was recorded as any exposure to prednisolone, cumulative prednisolone exposure, and time-adjusted mean daily prednisolone dose. Multivariate survival analyses were used to examine time-dependent associations of glucocorticoid use with damage accrual (defined as an increase of >= 1 on SDI). A SLEDAI-2K score of 0 was taken to indicate the absence of dinical and serological disease activity; a subset of patients without disease activity during the study were defined by a time-adjusted mean SLEDAI-2K (AMS) score of 0. Findings Between May 1,2013, and Dec 31,2016,1707 patients were recruited. Over a median observation period of 2.2 years (IQR 1.5-3.0), damage accrual events were observed in 255 (14.9%) patients. 1405 (82.3%) of patients were exposed to prednisolone, with a median time-adjusted mean prednisolone dose of 5.0 mg/day (IQR 1.9-8.8). As SLEDAI-2K and PGA scores were highly correlated, two multivariable models were set, each including one of these two variables. In the model including AMS score, baseline SDI damage (SDI >0) was independently associated with damage accrual (HR 1.32 [95% CI 1.01-1.73], p=0.0427). In the other model, time-adjusted mean PGA score was independently associated with damage accrual (1.05 [1.02-1.08], p=0.0012). In both models, factors independently associated with damage accrual included time-adjusted mean prednisolone dose, age at enrolment, and ethnicity (Asian vs non-Asians). 157 (9.2%) patients had an AMS score of 0 (no disease activity), among whom 103 (65.6%) had glucocorticoid exposure and the median time-adjusted mean prednisolone dose was 2.0 mg/day (IQR 0.0-5.0). Accrual of irreversible organ damage occurred in 21(13.4%) of these patients and was independently associated with time-adjusted mean prednisolone dose (HR 1.14 [95% CI 1.03-1.26], p=0.0117), time-adjusted mean PGA score (1.13 [1.03-1.23], p=0.0144), and age at enrolment (1.04 [1.01-1.07],p=0.0061), but not baseline SDI damage (0.94 [0.43-2.06], p=0.8675). Interpretation Glucocorticoid use contributes to damage accrual in systemic lupus erythematosus independently of the presence of clinical or serological disease activity. Copyright (C) 2019 Elsevier Ltd. All rights reserved.

Predictors of organ damage in Systemic Lupus Erythematosus in the Asia Pacific region: A systematic review

Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis

An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States

Factors Associated with Damage Accrual in Patients with Systemic Lupus Erythematosus with No Clinical or Serological Disease Activity: a Multicentre Cohort Study

[The Clinical Significance of Hematological Damage in Systemic Lupus Erythematosus and Related Antibodies].

Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies

Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort

Correlation between irreversible organ damage and the quality of life of patients with systemic lupus erythematosus: The Kyoto Lupus Cohort survey

Systemic lupus erythematosus and damage: What has changed over the past 20 years?

Non-simple genus minimizers in lens spaces

Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study

Long-term mortality and morbidity of patients with systemic lupus erythematosus: a single-center cohort study in China.

Regulation of glucose utilization in tumors by a stress-modified insulin: anti-insulin system.

Relationship between disease activity, organ damage and health-related quality of life in patients with systemic lupus erythematosus: A systemic review and meta-analysis

Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up

Preventing organ damage in systemic lupus erythematosus: the impact of early biological treatment

The Impact of Antibiotic Management on Resistance

Association of Systemic Lupus Erythematosus Standard of Care Immunosuppressants with Glucocorticoid Use and Disease Outcomes: a Multicentre Cohort Study

Lupus Low Disease Activity State and Remission and Risk of Mortality in Patients with Systemic Lupus Erythematosus: a Prospective, Multinational, Longitudinal Cohort Study

Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis

Differential impact of disease activity and damage on health-related quality of life in patients with systemic lupus erythematosus